| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
MapLight Therapeutics, Inc.
13D/A
MPLT · 56565P103
|
49.9% |
8/18/2026
Event 8/14/2026
|
||||
| Catalyst4, Inc. | 49.9% | |||||
| Robert Brown | 49.9% | |||||
| Ekemini Riley | 49.9% | |||||
| Mark Vorsatz | 49.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.